Nerve growth factor (NGF) mRNA (NGF mRNA)

Nerve growth factor (NGF) mRNA is the transcript of the NGF gene, which encodes a secreted protein essential for the growth, maintenance, and survival of certain target neurons (UniProt P01138). In the context of therapeutic development, NGF mRNA is targeted to modulate the levels of NGF protein, which is a key mediator of inflammatory and neuropathic pain (PubMed: 23454345). Elevated levels of NGF are associated with various chronic pain conditions, including osteoarthritis and interstitial cystitis, where it sensitizes nociceptors (PubMed: 15611753). Therapeutic strategies targeting the mRNA, such as antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs), aim to silence the expression of NGF at the pre-translational level to provide long-lasting analgesia. This approach offers a potential alternative to monoclonal antibodies that target the NGF protein directly, potentially reducing the frequency of administration. However, safety concerns include the risk of interfering with the neuroprotective functions of NGF and the challenge of achieving tissue-specific delivery to avoid systemic adverse effects (PubMed: 28835434). Research into NGF mRNA inhibition continues to explore its utility in treating conditions where protein-level inhibition has shown efficacy but also significant side effects.

Other names

Beta-nerve growth factor mRNANGF transcriptPro-NGF mRNA

Antisense inhibition or RNA interference (RNAi) to prevent the translation of Nerve growth factor protein (PubMed: 23454345).